Pancreatic Cancer Research

ResearcherUniversity of North Carolina at Chapel HillActive in the last 2 years

Mallory K. Roach

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0009-0006-9634-7755; OpenAlex author ID A5076912040; NIH RePORTER profile ID 79233391. Sources: OpenAlex.

Their work

Papers
3 (first author 1, last author 0)
Trials
0
Grants
1
Labs led
0
Collaborators
11
Papers, trials and grants by year

2025: 2 papers · 2026: 1 paper, 1 grant

Papers 3

  1. Vertical inhibition of the autophagy pathway impairs growth and enhances sensitivity to mTORC1 inhibition in pancreatic ductal adenocarcinoma Co-author DOI 10.64898/2026.06.28.734981↗
  2. Concurrent Inhibition of the RAS-MAPK Pathway and PIKfyve Is a Therapeutic Strategy for Pancreatic Cancer. First author DOI 10.1158/0008-5472.can-24-1757↗
  3. Combination of the MTA-Cooperative PRMT5 Inhibitor BMS-986504 and KRAS Inhibitors Is an Effective Treatment Strategy for MTAP-Deleted KRAS-Mutant Pancreatic Ca… Co-author DOI 10.1158/0008-5472.can-25-1507↗

Grants 1

  1. Assessing autophagic dependencies in the context of RAS inhibition in pancreatic ductal adenocarcinoma F31CA306329↗

Closest collaborators

The 11 strongest of 11 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Kirsten L. Bryant · 3 shared papers, 2025–2026 · strength 0.64
  2. Ryan N. Robb · 3 shared papers, 2025–2026 · strength 0.64
  3. Clint A. Stalnecker · 3 shared papers, 2025–2026 · strength 0.64
  4. Jonathan M. DeLiberty · 2 shared papers, 2025–2026 · strength 0.45
  5. Mariaelena Pierobon · 2 shared papers, 2025–2026 · strength 0.45
  6. Kristina Drizyte‐Miller · 2 shared papers, 2025 · strength 0.37
  7. Emanuel F. Petricoin · 2 shared papers, 2025 · strength 0.37
  8. Adrienne D. Cox · 2 shared papers, 2025 · strength 0.37
  9. Channing J. Der · 2 shared papers, 2025 · strength 0.37
  10. John P. Morris · 1 shared paper, 2025 · strength 0.19
  11. Sarah E. Ackermann · 1 shared paper, 2025 · strength 0.19

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.